Rafael Pharmaceuticals Enters into Collaboration with the National Institutes of Health (NIH) to Test CPI-613® (devimistat) in Cytokine Independent (Acute) HTLV-1 Associated Adult T-cell Leukemia/Lymphoma


You May Also Like

electroCore, Inc. Announces Second Quarter Financial Results

BASKING RIDGE, N.J., Aug. 13, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), ...

Vical Reports First Quarter 2018 Financial and Operational Results

SAN DIEGO, May 03, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial ...